BACKGROUND AND OBJECTIVES: Uromodulin-associated kidney disease (UAKD) is an autosomal dominant disease caused by uromodulin (UMOD) gene mutations. This study explored genotype-phenotype correlations by examining the relationship between the type of UMOD mutation and the age at onset of ESRD. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Extensive bibliographic research was used to ascertain patient-level data of all patients with UAKD published up to October 2011. Data included sex; ages at onset of hyperuricemia, gout, and ESRD; and UMOD genotype. Kaplan-Meier analysis and Cox proportional hazards models fitted with shared gamma frailty terms to adjust for within-family correlations were used to model time to event. RESULTS: Thirty-one peer-reviewed publications reporting on 202 patients from 74 families with 59 different UMOD mutations were included. Median ages at onset of hyperuricemia, gout, and ESRD were 24, 40, and 56 years, respectively. Men developed gout and ESRD significantly earlier than did women (age at ESRD was 50 years for men and 60 for women; P=0.04, shared frailty model). Median ages at ESRD development were lowest with Cys77Tyr (37.5 years) and highest with Gln316Pro (65.5 years) UMOD mutations. Onset of ESRD was significantly earlier with UMOD mutations located within the epidermal growth factor domains 2 and 3 (range, 45-52 years; P<0.01 and 0.04, respectively) compared with the cysteine-rich domains (range, 60-65 years; by shared frailty model). CONCLUSIONS: The UMOD genotype is related to the clinical phenotype of UAKD. This finding may assist in counseling of patients.
BACKGROUND AND OBJECTIVES: Uromodulin-associated kidney disease (UAKD) is an autosomal dominant disease caused by uromodulin (UMOD) gene mutations. This study explored genotype-phenotype correlations by examining the relationship between the type of UMOD mutation and the age at onset of ESRD. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Extensive bibliographic research was used to ascertain patient-level data of all patients with UAKD published up to October 2011. Data included sex; ages at onset of hyperuricemia, gout, and ESRD; and UMOD genotype. Kaplan-Meier analysis and Cox proportional hazards models fitted with shared gamma frailty terms to adjust for within-family correlations were used to model time to event. RESULTS: Thirty-one peer-reviewed publications reporting on 202 patients from 74 families with 59 different UMOD mutations were included. Median ages at onset of hyperuricemia, gout, and ESRD were 24, 40, and 56 years, respectively. Men developed gout and ESRD significantly earlier than did women (age at ESRD was 50 years for men and 60 for women; P=0.04, shared frailty model). Median ages at ESRD development were lowest with Cys77Tyr (37.5 years) and highest with Gln316Pro (65.5 years) UMOD mutations. Onset of ESRD was significantly earlier with UMOD mutations located within the epidermal growth factor domains 2 and 3 (range, 45-52 years; P<0.01 and 0.04, respectively) compared with the cysteine-rich domains (range, 60-65 years; by shared frailty model). CONCLUSIONS: The UMOD genotype is related to the clinical phenotype of UAKD. This finding may assist in counseling of patients.
Authors: J J O Turner; J M Stacey; B Harding; P Kotanko; K Lhotta; J G Puig; I Roberts; R J Torres; R V Thakker Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958
Authors: Anthony J Bleyer; Howard Trachtman; Jaspreet Sandhu; Michael C Gorry; Thomas C Hart Journal: Am J Kidney Dis Date: 2003-08 Impact factor: 8.860
Authors: Paul Jennings; Sonia Aydin; Peter Kotanko; Judith Lechner; Karl Lhotta; Sian Williams; Rajesh V Thakker; Walter Pfaller Journal: J Am Soc Nephrol Date: 2006-12-06 Impact factor: 10.121
Authors: Aleksander Prejbisz; Lorenz Sellin; Elżbieta Szwench-Pietrasz; Magdalena Woznowski; Ilona Michałowska; Dirk Blondin; Dariusz Sajnaga; Jorg T Epplen; Mieczysław Litwin; Gabriele Dekomien; Magdalena Januszewicz; Udo Helmchen; Joanna Matuszkiewicz-Rowińska; Marcin Adamczak; Andrzej Więcek; Andrzej Januszewicz; Lars C Rump Journal: Kidney Int Date: 2015-02-11 Impact factor: 10.612
Authors: Bryce G Johnson; Lan T Dang; Graham Marsh; Allie M Roach; Zebulon G Levine; Anthony Monti; Deepak Reyon; Lionel Feigenbaum; Jeremy S Duffield Journal: J Clin Invest Date: 2017-10-09 Impact factor: 14.808
Authors: Kai-Uwe Eckardt; Seth L Alper; Corinne Antignac; Anthony J Bleyer; Dominique Chauveau; Karin Dahan; Constantinos Deltas; Andrew Hosking; Stanislav Kmoch; Luca Rampoldi; Michael Wiesener; Matthias T Wolf; Olivier Devuyst Journal: Kidney Int Date: 2015-03-04 Impact factor: 10.612
Authors: Anthony J Bleyer; Matthias T Wolf; Kendrah O Kidd; Martina Zivna; Stanislav Kmoch Journal: Pediatr Nephrol Date: 2021-05-22 Impact factor: 3.651